Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Capecitabine + Oxaliplatin + Tislelizumab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Capecitabine||Xeloda||R340||Chemotherapy - Antimetabolite 11||Xeloda (capecitabine) is an antimetabolite that when activated to 5-FU ultimately inhibits DNA synthesis and cell division (NCI Drug Dictionary).|
|Oxaliplatin||Eloxatin||Diaminocyclohexane Oxalatoplatinum||Chemotherapy - Platinum 6||Eloxatin (oxaliplatin) is comprised of a platinum complex, which causes DNA-platinum cross-links, inhibition of DNA replication and transcription, and cell toxicity, and is FDA approved for colorectal cancer (FDA.gov).|
|Tislelizumab||BGB-A317||Immune Checkpoint Inhibitor 94 PD-L1/PD-1 antibody 65||Tislelizumab (BGB-A317) is a human monoclonal antibody that targets PD-1 (PDCD1), thereby blocking the binding of PD-L1 (CD274) and potentially resulting in activation of a T-cell immune response against tumor cells (PMID: 32769013, PMID: 32561638, PMID: 32540858).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||gastroesophageal adenocarcinoma||not applicable||Capecitabine + Oxaliplatin + Tislelizumab||Phase II||Actionable||In a Phase II trial, Tislelizumab (BGB-A317) in combination with Eloxatin (oxaliplatin) and Xeloda (capecitabine) demonstrated tolerability in patients with advanced gastric adenocarcinoma or gastroesophageal junction adenocarcinoma and resulted in an objective response rate of 46.7% (7/15, all partial responses), disease control rate of 80% (12/15), median time to response of 9.3 weeks, and median progression-free survival of 6.1 months (PMID: 32561664; NCT03469557).||32561664|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03777657||Phase III||Capecitabine + Oxaliplatin Cisplatin + Fluorouracil Capecitabine + Oxaliplatin + Tislelizumab Cisplatin + Fluorouracil + Tislelizumab||Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma||Recruiting|